Vutrisiran, sold under the brand name Amvuttra, is a medication used for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. From Wikipedia
The heart disease drug met primary goals but fell short of investor expectations, leading to a significant stock drop.
